The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Exploring a Career in Nursing: What You Need to Know
- Back-to-School Wellness — A Resource for Families and Providers
- The Summer Injury Spike: Common ER Visits and How to Prevent Them
- Men’s Health Month – Closing Gaps in Prevention and Early Detection
- Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers